Preet Paul Singh
Overview
Explore the profile of Preet Paul Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navari R, Le-Rademacher J, Smieliauskas F, Ruddy K, James Saphner T, Liu H, et al.
Oncologist
. 2023 Jun;
28(8):722-729.
PMID: 37284847
Purpose: A protocol was developed to evaluate the value of an NK-1 receptor antagonist for preventing nausea and vomiting resulting from highly emetogenic chemotherapy when an olanzapine-based antiemetogenic regimen was...
2.
Patel S, Othus M, Chae Y, Giles F, Hansel D, Paul Singh P, et al.
Clin Cancer Res
. 2020 Jan;
26(10):2290-2296.
PMID: 31969335
Purpose: Immune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine...
3.
Lakshman A, Paul Singh P, Rajkumar S, Dispenzieri A, Lacy M, Gertz M, et al.
Am J Hematol
. 2017 Oct;
93(2):179-186.
PMID: 29067723
Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE-like regimens: VPLRs) outside TOTAL THERAPY trials is limited. We analyzed the outcomes...
4.
Arora N, Gupta A, Paul Singh P
J Gastrointest Oncol
. 2017 Jul;
8(3):485-498.
PMID: 28736636
Biological therapy comprises agents that by virtue of their unique mechanisms of action, are able to specifically incite a response against or target malignant cells. They differ from conventional chemotherapy...
5.
Gupta A, Majumder K, Arora N, Mayo H, Paul Singh P, Beg M, et al.
Lung Cancer
. 2016 Dec;
102:49-59.
PMID: 27987589
Objectives: We aimed to assess the association between premorbid obesity, measured using body mass index (BMI) and lung cancer-related mortality, through a systematic review and meta-analysis. Materials And Methods: Observational...
6.
Paul Singh P, Shi Q, Foster N, Grothey A, Nair S, Chan E, et al.
Oncologist
. 2016 Nov;
21(12):1509-1521.
PMID: 27881709
Background: Preclinical and epidemiological data suggest that metformin might have antineoplastic properties against colon cancer (CC). However, the effect of metformin use on patient survival in stage III CC after...
7.
Paul Singh P, Sharma P, Krishnan G, Lockhart A
Gastroenterol Rep (Oxf)
. 2015 Oct;
3(4):289-97.
PMID: 26510455
Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy...
8.
Majumder K, Gupta A, Arora N, Paul Singh P, Singh S
Clin Gastroenterol Hepatol
. 2015 Oct;
14(3):355-368.e.
PMID: 26460214
Background & Aims: Obesity is associated with an increased risk for pancreatic cancer, but it is unclear whether it affects mortality. We performed a systematic review and meta-analysis to assess...
9.
10.
Singh S, Paul Singh P, Murad M, Singh H, Samadder N
Am J Gastroenterol
. 2014 Jun;
109(9):1375-89.
PMID: 24957158
Objectives: We performed meta-analysis to estimate pooled prevalence, risk factors, and outcomes of interval colorectal cancers (CRCs). Methods: Systematic literature search through October 2013, identified population-based studies, reporting prevalence of...